Author of

• 25971

  +

  P3.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 983)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27795

    +

    P3.17-03 - Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated with Combination of Chemotherapy and Conformal Radiotherapy (ID 11330)

    12:00 - 13:30  |  Presenting Author(s): Simonida Crvenkova
    • Abstract
    • Slides

    Background
    

    Background: Combined modality therapy is standard of care for patients with unrespectable locally advanced non-small cell, however, insufficient data are available regarding what is the best combination of chemotherapy and radiotherapy.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Methods: To evaluate the treatment results, study of 85 patients was randomly assigned to one of the two treatment arms. In the sequential arm, 45 patients had previously received sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal radiotherapy (RT). In the second concurrent arm, 40 patients received concomitant chemotherapy of cisplatine and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy of carboplatine and etoposide. We described all phases of the conformal RT.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Results: From October 2005 to April 2008, 85 patients were enrolled. The median survival was 13 months for the patients in the sequential arm and 19 months for those in the concurrent treatment arm. The differences were statistically significant (log-rank test p=0.0039) Figure 1. The disease-free survival was 9 months in the sequential arm and 16 months in the concurrent treatment group. The differences were statistically significant (log-rank test p=0.0023). Treatment-related toxicities were assessed according RTOG/EORTC criteria. Acute esophagitis and incidence of neutropenia were higher in the concurrent arm.. Grade 3 esophagitis was characteristic only for concurrent treatment and it was reason for radiotherapy interruption, but no longer than 7 days.
    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Conclusions: Given the higher toxicity in the concurrent-consolidation schedule, it should be reserved for patients younger than 70 years, having good performance status and minimal weight loss.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.